Mobilan

Mobilan is a nanoparticle-formulated, recombinant non-replicating adenovirus in preclinical development as a universal cancer therapy by our Panacela Labs, Inc. subsidiary.

In preclinical studies, delivery of Mobilan to tumor cells caused constant toll-like receptor 5 (TLR5) signaling that induced innate immune response to the tumor with subsequent development of adaptive immune response.